Lumea announces availability of Cxbladder tests on BxLink platform
This partnership is revolutionizing bladder cancer diagnostics with seamless access to non-invasive genomic testing and enhanced clinical efficiency
3 Jan 2025
Lumea, a leader in digital pathology solutions, has announced that Cxbladder™, a suite of non-invasive genomic urine tests optimized for the risk stratification and surveillance of urothelial cancer (UC), is now fully integrated into its BxLink™ digital pathology platform.
This partnership empowers healthcare providers with streamlined access to Cxbladder’s advanced diagnostic capabilities, further enhancing patient care and clinical efficiency.
Cxbladder’s suite of urine-based tests provides an innovative solution for the risk stratification of UC in patients presenting with hematuria and those being monitored for recurrent non-muscle invasive bladder cancer (NMIBC). The tests help prioritize time and clinical resources for those who need it the most, streamlining practice workflow and increasing overall efficiency. Non-invasive sampling, coupled with the option of in-home sample collection, ensures patients get the best experience possible.
Lumea customers who currently order Cxbladder can now streamline and simplify their workflow by requesting the test digitally. Additionally, customers new to Cxbladder can quickly begin ordering the test and explore its use with eligible patient types.
Providers using BxLink can easily access Cxbladder’s suite of tests, allowing faster integration of these groundbreaking diagnostics into everyday practice. The platform’s advanced capabilities ensure that every step of the process—from test ordering to result retrieval is as seamless as possible, allowing clinicians to focus on what matters most: their patients.
“The ability to order Cxbladder tests through the BxLink digital pathology platform from Lumea is a great example of Pacific Edge’s digitalization strategy to improve the customer experience with elegant ordering and resulting of our tests,” says Pacific Edge’s CEO, Dr Peter Meintjes. “This will result in more satisfied customers who we hope will more consistently order our Cxbladder tests on eligible patient types for microhematuria and bladder cancer surveillance. In particular, BxLink is a ‘one-to-many’ interface, where a single integration makes Cxbladder available to every Lumea customer already using BxLink simultaneously with a single deployment.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>